Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
T cells, as well as depleted primarily immunosuppressive M2 macrophages. These results demonstrate that tumor-targeted oxaliplatin(IV)-based prodrugs carrying TLR7/8 agonists offer a potent dual-release strategy for improved immunochemotherapy, while minimizing excessive immune responses associated with systemic TLR7/8 activation.
Authors
- Christian R. Kowol (ORCID: https://orcid.org/0000-0002-8311-1632)
- Martijn Dijkstra (ORCID: https://orcid.org/0000-0001-8345-8196)
- Michael Gutmann (ORCID: https://orcid.org/0000-0002-2253-4578)
- Philipp Salomon (ORCID: https://orcid.org/0009-0000-7355-4141)
- Petra Heffeter (ORCID: https://orcid.org/0000-0001-6401-8646)
- Bernhard K. Keppler (ORCID: https://orcid.org/0000-0003-0877-1822)
- C. Pirker
- Walter Berger (ORCID: https://orcid.org/0000-0003-0014-1658)
- Maria Sibilia (ORCID: https://orcid.org/0000-0001-6129-5613)
- James Cowles
- Dina Baier (ORCID: https://orcid.org/0000-0002-4328-7035)
- Carola Jaunecker (ORCID: https://orcid.org/0009-0000-2589-1880)
- Anja Federa
- Dietmar Herndler-Brandstetter
- Iemima Semerean
- Venla Karvonen
Institutions
- University of Vienna (AT)
- Comprehensive Cancer Center Vienna (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1002/advs.202514588
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Austrian Science Fund